SITE003-0008

SITE003 (CAN) › SITE003-0008

SITE003-0008

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2025-08-25

completed

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-23 (study day 201); relationship: RELATED

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 134); relationship: not assessed

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-04-29 (study day 54); relationship: NOT RELATED

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-03-30 (study day 24); relationship: not assessed

moderate assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-03-16 (study day 10); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.